Ghent University Academic Bibliography

Advanced

Lipoprotein lipase SNPs rs13702 and rs301 correlate with clinical outcome in chronic lymphocytic leukemia patients

Ans Rombout, Basile Stamatopoulos, Laurence Lagneaux, Sofie Lust, Fritz Offner UGent, Evelien Naessens UGent, Hanne Vanderstraeten, Bruno Verhasselt UGent and Jan Philippé UGent (2015) PLOS ONE. 10(3).
abstract
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and is characterized by a heterogeneous clinical course. This variability in clinical course has spiked the search for prognostic markers able to predict patient evolution at the moment of diagnosis. Markers demonstrated to be of value are the mutation status of the immunoglobulin heavy chain variable region genes (IGHV) and lipoprotein lipase (LPL) expression. High LPL mRNA expression has been associated with short treatment free (TFS) and decreased overall survival (OS) in CLL. The LPL SNPs rs301 (T<C), rs328 (C<G) and rs13702 (T<C) have been associated with various metabolic disorders, but the association with CLL evolution is unknown. Here, in a cohort of 248 patients, we show that patients with the LPL SNP rs13702 wild-type T/T genotype had significantly shorter OS than patients with C/C and T/C genotypes (median time until CLL related death: 90 and 156 months respectively, p=0.008). The same was observed for LPL SNP rs301 (median time until CLL related death T/T: 102 and C/C, T/C: 144 months, p=0.03). Both SNPs rs301 and rs13702 were significantly associated with each other and notably, no association was found between IGHV status and presence of the SNP genotypes, indicating that these LPL SNPs are reliable prognostic markers that could add extra prognostic and predictive information to classical markers and help to improve the management of CLL.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
PROMOTER, VARIANT, PHENOTYPE, RISK, SURVIVAL, MESSENGER-RNA EXPRESSION, GAIN
journal title
PLOS ONE
PLoS One
volume
10
issue
3
article number
e0121526
pages
15 pages
Web of Science type
Article
Web of Science id
000356353700110
JCR category
MULTIDISCIPLINARY SCIENCES
JCR impact factor
3.057 (2015)
JCR rank
11/63 (2015)
JCR quartile
1 (2015)
ISSN
1932-6203
DOI
10.1371/journal.pone.0121526
language
English
UGent publication?
yes
classification
A1
additional info
correction published in PLoS One (2015) 10(6), e0131029 ; DOI 10.1371/journal.pone.0131029
copyright statement
I have retained and own the full copyright for this publication
id
6835847
handle
http://hdl.handle.net/1854/LU-6835847
date created
2015-06-19 11:08:20
date last changed
2016-12-21 15:41:16
@article{6835847,
  abstract     = {Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and is characterized by a heterogeneous clinical course. This variability in clinical course has spiked the search for prognostic markers able to predict patient evolution at the moment of diagnosis. Markers demonstrated to be of value are the mutation status of the immunoglobulin heavy chain variable region genes (IGHV) and lipoprotein lipase (LPL) expression. High LPL mRNA expression has been associated with short treatment free (TFS) and decreased overall survival (OS) in CLL. The LPL SNPs rs301 (T{\textlangle}C), rs328 (C{\textlangle}G) and rs13702 (T{\textlangle}C) have been associated with various metabolic disorders, but the association with CLL evolution is unknown. Here, in a cohort of 248 patients, we show that patients with the LPL SNP rs13702 wild-type T/T genotype had significantly shorter OS than patients with C/C and T/C genotypes (median time until CLL related death: 90 and 156 months respectively, p=0.008). The same was observed for LPL SNP rs301 (median time until CLL related death T/T: 102 and C/C, T/C: 144 months, p=0.03). Both SNPs rs301 and rs13702 were significantly associated with each other and notably, no association was found between IGHV status and presence of the SNP genotypes, indicating that these LPL SNPs are reliable prognostic markers that could add extra prognostic and predictive information to classical markers and help to improve the management of CLL.},
  articleno    = {e0121526},
  author       = {Rombout, Ans and Stamatopoulos, Basile and  Lagneaux, Laurence and Lust, Sofie and Offner, Fritz and Naessens, Evelien and Vanderstraeten, Hanne and Verhasselt, Bruno and Philipp{\'e}, Jan},
  issn         = {1932-6203},
  journal      = {PLOS ONE},
  keyword      = {PROMOTER,VARIANT,PHENOTYPE,RISK,SURVIVAL,MESSENGER-RNA EXPRESSION,GAIN},
  language     = {eng},
  number       = {3},
  pages        = {15},
  title        = {Lipoprotein lipase SNPs rs13702 and rs301 correlate with clinical outcome in chronic lymphocytic leukemia patients},
  url          = {http://dx.doi.org/10.1371/journal.pone.0121526},
  volume       = {10},
  year         = {2015},
}

Chicago
Rombout, Ans, Basile Stamatopoulos, Laurence Lagneaux, SOFIE LUST, Fritz Offner, Evelien Naessens, Hanne Vanderstraeten, Bruno Verhasselt, and Jan Philippé. 2015. “Lipoprotein Lipase SNPs Rs13702 and Rs301 Correlate with Clinical Outcome in Chronic Lymphocytic Leukemia Patients.” Plos One 10 (3).
APA
Rombout, A., Stamatopoulos, B., Lagneaux, L., LUST, S., Offner, F., Naessens, E., Vanderstraeten, H., et al. (2015). Lipoprotein lipase SNPs rs13702 and rs301 correlate with clinical outcome in chronic lymphocytic leukemia patients. PLOS ONE, 10(3).
Vancouver
1.
Rombout A, Stamatopoulos B, Lagneaux L, LUST S, Offner F, Naessens E, et al. Lipoprotein lipase SNPs rs13702 and rs301 correlate with clinical outcome in chronic lymphocytic leukemia patients. PLOS ONE. 2015;10(3).
MLA
Rombout, Ans, Basile Stamatopoulos, Laurence Lagneaux, et al. “Lipoprotein Lipase SNPs Rs13702 and Rs301 Correlate with Clinical Outcome in Chronic Lymphocytic Leukemia Patients.” PLOS ONE 10.3 (2015): n. pag. Print.